Cardiac Energetics and Function in Normal Human Ageing

Newcastle-upon-Tyne Hospitals NHS Trust

Status: Completed

Conditions: Ageing; Left Ventricular Function Diastolic Dysfunction; Left Ventricular Function Systolic Dysfunction

Treatments: Drug: Ramipril

Study type: Interventional

Funder types: Other

Identifiers

NCT01504828

BH111454

95309 (Other Identifier)

Details and patient eligibility

About

Normal aging is characterized by altered cardiovascular function. Our preliminary data with MR imaging and spectroscopy in normal subjects without cardiovascular disease or hypertension show that age-related cardiac dysfunction is characterized initially by impaired relaxation of the heart (40 - 60 years), and then at > 60 years altered contraction and impaired myocardial energetics. For the first time, the investigators will test whether the functional and energetic effects of normal aging can be reversed by acutely reducing stiffness of peripheral blood vessels using an ACE inhibitor. This will potentially have important insights into how normal aging affects the heart, and how potential treatments could be used to attenuate this process.

Full description

Normal aging is characterized by altered cardiovascular function. Our preliminary data with MR imaging and spectroscopy in normal subjects without cardiovascular disease or hypertension show that age-related cardiac dysfunction is characterized initially by diastolic dysfunction (40 - 60 years), and then at > 60 years altered systolic strains and impaired myocardial energetics. The investigators propose to study the mechanism of these findings in subjects with normal aging without any cardiovascular disease, hypothesizing that increased vascular stiffening contributes to impaired energetics and left ventricular function. For the first time, the investigators will test whether the functional and energetic effects of normal aging can be reversed by acutely reducing afterload using an ACE inhibitor. This will be tested at 2 ages (40-60 and > 60 years), so that the intervention tests the hypothesis soon after the abnormalities develop (40-60 years - diastolic dysfunction; > 60 years energetics and altered strains). This will potentially have important insights into how normal aging affects the heart, and how potential treatments could be used to attenuate this process.

Enrollment: 135 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male and female subjects between the ages of 20 and 80 years

Exclusion criteria

• Any cardiovascular condition including hypertension, or on any cardiovascular therapy.
• Blood Pressure > 150 mmHg systolic, and/or > 90 mmHg diastolic
• Claustrophobia
• Implanted metal prosthesis
• Chronic renal failure requiring dialysis
• Diabetes mellitus.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

135 participants in 1 patient group

Ramipril

Experimental group

Description:

Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function

Treatment:

Drug: Ramipril